Coya Therapeutics Appoints Director Mark Pavao to Audit Committee

What Happened
Coya Therapeutics, Inc. filed an Amendment No. 1 to its Form 8-K (originally filed April 2, 2026) to report that on August 6, 2026 the Board of Directors, following the Nominating and Corporate Governance Committee's recommendation, appointed Mark H. Pavao to the Audit Committee, effective immediately. Mr. Pavao was previously disclosed as a director effective April 1, 2026.

Key Details

• Filing: Amendment No. 1 to Current Report on Form 8-K/A, filed Aug. 7, 2026 (amends original 8-K filed Apr. 2, 2026).
• Appointment date: Mark H. Pavao joined the Audit Committee effective August 6, 2026.
• Audit Committee members after appointment: Dr. Dov Goldstein (Chair), Dr. Ann Lee, Dieter Weinand, and Mark H. Pavao.
• Governance action made upon recommendation of the Nominating and Corporate Governance Committee (Item 5.02 disclosure).

Why It Matters
This is a governance update that affects the board committee overseeing financial reporting, audits, and internal controls. For investors, changes to the Audit Committee’s membership are relevant because that committee plays a direct role in oversight of the company’s financial statements and disclosure controls. The filing simply updates committee composition and contains no financial disclosures or operational changes.